skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Lanreotide Long-Acting Aqueous Gel (Code C65111)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lanreotide Long-Acting Aqueous Gel

Definition: A long-acting aqueous gel preparation of lanreotide, a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide inhibits the secretion of growth hormone (GH) by binding to pituitary somatostatin receptors, and may inhibit the release of various other hormones, including thyroid stimulating hormone (TSH) and the gastroenteropancreatic hormones insulin, glucagon and gastrin. This agent also decreases circulating total and free insulin-like growth factor 1 (IGF-I). Lanreotide exhibits a high binding affinity for somatostatin receptor 2 (SSTR-2) and a lesser binding affinity for SSTR-5. However, compared to octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland.

Display Name: Lanreotide Long-Acting Aqueous Gel

Label: Lanreotide Long-Acting Aqueous Gel

NCI Thesaurus Code: C65111 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831852  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
lanreotide (long-acting aqueous preparation)
Lanreotide Autogel
Lanreotide Long-Acting Aqueous Gel
Somatuline Autogel

External Source Codes: 
PDQ Closed Trial Search ID 486962
PDQ Open Trial Search ID 486962 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831852

Other Properties:
     Name Value (qualifiers indented underneath)
code C65111
Contributing_Source CTRP
Legacy_Concept_Name Lanreotide_Long-Acting_Aqueous_Gel
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom